Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.

Authors

Institutions

Publication Details

Journal
Blood Advances
Published
2025-07-16
DOI
https://doi.org/10.1182/bloodadvances.2025016661
Citations
2
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
2.94

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

José Antonio Hueso, Daniel García Belmonte, Antonio M. Gutierrez, Pau Abrisqueta et al.
2 citations
Blood Advances
Lymphoma Diagnosis and Treatment
2.94
article

Tafasitamab plus lenalidomide as salvage therapy in diffuse large B-cell lymphoma: real-world experience from GELTAMO

José Antonio Hueso, Daniel García Belmonte, Antonio M. Gutierrez, Pau Abrisqueta, Pilar Gómez‐Prieto, Andrés Provencio, Ana Jiménez Ubieto, Pilar Bravo, Ana García‐Noblejas, Aránzazu Alonso, Marı́a N. Navarro, Teresa Knight, Mariana Bastos‐Oreiro, María Stefanía Infante, Francisco José Gonzalvo Ibáñez, Sandra Perez, María de Lourdes Rodríguez Pérez, Eva M. González-Barca, Sara Nistal, Julio Dávila, Pilar Martinez‐Barranco, María Jesús Peñarrubia, Izaskun Zeberio, Luis Palomera, Ángeles Fernández, Javier López-Marín, Guillermo Rodríguez‐Domínguez, Ainara Ferrero, Haridian de la Nuez, Xabier Martin, Daniel Morillo, Jaime Pérez de Oteyza, Rubén Fernández, Concepción Nicolás, Alejandro Marin, Sonia González, Elena Pérez, Eva Donato, Maria Victoria Calle Gordo, Diana Sanchez-Arguello, Francisco Javier Penalvar
article en
2 citations

Abstract

Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) remains challenging to treat, especially in patients ineligible for intensive therapy or chimeric antigen receptor T cells. Tafasitamab plus lenalidomide (T/L) is an effective option based on the phase 2 L-MIND trial findings, although real-world evidence studies have not consistently confirmed these results. We aimed to describe real-world outcomes of R/R DLBCL treated with T/L in Spain. A total of 99 patients received at least 1 dose of tafasitamab (intent-to-treat [ITT] cohort), with 83 completing at least 1 full cycle of T/L (efficacy cohort). Respectively for ITT and efficacy cohorts, at a median follow-up of 19.2 and 21.6 months, the overall response rate was 51% and 61% (complete response [CR], 35% and 42%). Median duration of response was not reached, and patients achieving a CR had excellent outcomes. The median progression-free survival (PFS) was 4.9 and 10.9 months, and overall survival (OS) was 12.2 and 21.8 months, respectively for both ITT and efficacy cohorts. Neither age nor cumulative illness rating score influenced survival. Better PFS was obtained in first/second relapse but only poor Eastern Cooperative Oncology Group performance status 2 to 4, double-hit lymphoma, and those with refractory/progressing disease after the previous therapy, were independently associated with worse PFS. Treatment was generally well tolerated, with manageable toxicity. Relative dose intensity of lenalidomide significantly affected response, PFS, and OS. In summary, T/L is both well tolerated and effective, irrespective of age or comorbidities. Our findings provide valuable insights into the real-world application of T/L and reinforce its role as a key treatment option for patients with R/R DLBCL.

Blood AdvancesVol. 9(19)
Universidad San Pablo CEU (ES), Catholic University of Ávila (ES), Hospital Universitario La Paz (ES), Hospital Universitari Arnau de Vilanova (ES), Hospital General Universitario Gregorio Marañón (ES), Research Institute Hospital 12 de Octubre (ES), Institut d'Investigació Biomédica de Bellvitge (ES), Hospital Universitario Nuestra Señora de Candelaria (ES), Hospital General Universitario Morales Meseguer (ES), Doctors Hospital of Laredo (US), Hospital La Luz (ES), Hospital Universitario de Gran Canaria Doctor Negrín (ES), Marqués de Valdecilla University Hospital (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Universitario 12 De Octubre (ES), Ayuntamiento de Castellón de la Plana (ES), Fundación Hospital Manacor (ES), Hospital Universitario Puerta de Hierro Majadahonda (ES), Institut Català d'Oncologia (ES), Hospital Universitario Quirónsalud Madrid (ES), Hospital Universitario HM Madrid (ES), Hospital Arnau de Vilanova (ES), Hospital General Universitari de Castelló (ES), Hospital Universitario Doctor Peset (ES), Vall d'Hebron Hospital Universitari (ES), Hospital Universitario Fundación Jiménez Díaz (ES), Hospital Universitario de La Princesa (ES), Hospital Universitario Central de Asturias (ES), Hospital Clínico Universitario Lozano Blesa (ES), Instituto de Investigación Sanitaria Aragón (ES), Hospital de Cruces (ES), Hospital Universitario HM Sanchinarro (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Donostiako Unibertsitate Ospitalea (ES), Fundación Hospital Provincial de Castellón (ES), Hospital Universitario Lucus Augusti (ES), Hospital General de Elda (ES), Hospital Universitario de Fuenlabrada (ES), Hospital Universitario De Cabueñes (ES), Hospital Vega Baja (ES), Complejo Hospitalario Torrecárdenas (ES), Hospital Universitario Son Espases (ES), Hospital Universitario Virgen del Rocío (ES), Hospital Clínico Universitario de Valladolid (ES), Hospital Xeral Calde (ES), Complejo Hospitalario de Pontevedra (ES), Hospital Universitario Infanta Leonor (ES), Hospital Nuestra Señora de Alarcos (ES), Hospital Universitario Sanitas La Zarzuela (ES)
Incyte
Openalex Percentile: Top 9%
Lymphoma Diagnosis and Treatment
2.94
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.